Mia's treatment
How has Mia been treated in the past?
Mia has tried many treatments over the six years that she suffered from moderate-to-severe psoriasis, but none so far have had any long-term benefits.
In this animation, Mia, her parents and her doctor thoroughly review her treatment history and discuss what has worked and what has caused unacceptable side effects.
Such discussions are invaluable in the shared decision-making treatment approach. As Mia is approaching adolescence, a critical point in the development of emotional and psychosocial well-being25, her parents and doctor are keen to keep trying new treatment options which could work for Mia.
Find out what treatments could be available for Mia soon
Continue on to find out what paediatric psoriasis clinical guidelines recommend and the latest data for approved treatments.
Are we caring enough for Mia?
Paediatric psoriasis treatment guidelines were previously limited
Societies, associations and institutes develop clinical guidelines for the treatment and management of psoriasis at local, national, and international levels.
International guidelines for psoriasis in adults have been shown to be relatively consistent concerning older biologic therapies, but differing when it came to switching biologics, monitoring outcomes and combining therapies1.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
A number of treatments are approved or recommended for use in children with moderate-to-severe psoriasis
Psoriasis treatment in adults is largely based on disease severity determined by the % of body surface (BSA) affected2:
- <3% BSA considered mild
- 3–10% BSA considered moderate
- >10% BSA considered severe
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Current treatments are not always effective in the real world
The efficacy of biologics for childhood psoriasis and effect on quality of life (QoL) is certainly impressive from the clinical trial data but could this data be considered a ‘best-case scenario’ given that patients with more severe disease and/or comorbidities may not have been eligible to be included in the clinical trials? How does this compare with real-world data?
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
References
- Stiff KM, Glines KR, Porter CL, Cline A, Feldman SR. Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis. Expert Review of Clinical Pharmacology. 2018;11(12):1209–1218.
- Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
of interest
are looking at
saved
next event
Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Novartis Pharma AG, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.